Previous 10 | Next 10 |
MARIETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2023 after the market close on Monday, Octob...
2023-10-04 05:43:37 ET Summary MiMedx had strong Q2 2023 performance, particularly in Wound & Surgical; operational efficiency achieved but concerns over disbanding Regenerative Health division. Balance sheet healthy; liquidity robust but market signals caution with equity dil...
MARIETTA, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIEFFECT™, the Company’s latest addition to its portfolio of AWC solutions. EPIEFFECT expands the Company&...
YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a research collaboration agreement with MIMEDX Group, Inc (Nasdaq: ...
2023-08-01 18:48:03 ET MiMedx Group, Inc. (MDXG) Q2 2023 Earnings Conference Call August 01, 2023 05:00 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference...
2023-08-01 16:19:28 ET MiMedx Group press release ( NASDAQ: MDXG ): Q2 GAAP EPS of $0.00 beats by $0.03 . Revenue of $81.3M (+21.6% Y/Y) beats by $6.47M . As a result of our progress to date, we are increasing guidance for our full-year 2023 net sales percentag...
Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive as Chief Financial Officer Management to Host Conference Call on Tuesday...
2023-07-31 17:35:53 ET MiMedx Group ( NASDAQ: MDXG ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, after market close. The consensus EPS Estimate is -$0.03 and the consensus Revenue Estimate is $74.83M (+11.9% Y/Y). For further details see: ...
2023-07-25 08:11:12 ET Summary MiMedx has announced its intention to exit the knee osteoarthritis business to instead focus efforts on the high-growth Wound biologics market. The restructuring is expected to improve cash flow and profitability, supporting a positive long-term outl...
MARIETTA, Ga., July 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 1...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 07:00:07 ET Ross Osborn from Cantor Fitzgerald issued a price target of $11.00 for MDXG on 2024-07-02 06:15:00. The adjusted price target was set to $11.00. At the time of the announcement, MDXG was trading at $6.7. The overall price target consensus is at $10...
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company’s Senior Vice President, Sales si...
2024-06-13 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...